CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Timothy P. Hickling Ian D. Broadbent |
| Publication date | August 21, 2013 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |